Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension
- 1 October 2013
- journal article
- research article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 156 (4), 731-736.e2
- https://doi.org/10.1016/j.ajo.2013.05.016
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115JAMA Ophthalmology, 2013
- The Effect of Rho-Associated Protein Kinase Inhibitor on Monkey Schlemm's Canal Endothelial CellsInvestigative Opthalmology & Visual Science, 2012
- Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular HypertensionAmerican Journal of Ophthalmology, 2011
- GlaucomaThe Lancet, 2011
- Current and emerging medical therapies in the treatment of glaucomaEmerging Drugs, 2011
- Intraocular Pressure–Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy VolunteersAmerican Journal of Ophthalmology, 2008
- Effects of Topical Administration of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Ocular Tissues in Rabbits and MonkeysPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cellsExperimental Eye Research, 2006
- Racial Differences in the Cause-Specific Prevalence of Blindness in East BaltimoreNew England Journal of Medicine, 1991